U.K. regulators MHRA approved Wegovy for risk of major cardiovascular events
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy (semaglutide) for a new purpose: to help reduce the risk of heart problems in people who are overweight or obese. Specifically, the drug has been approved for individuals with a body mass index (BMI) of 27 or over who have already been diagnosed Read more: U.K. regulators MHRA approved Wegovy for risk of major cardiovascular events..